Opioid antagonist previously approved in injectable and nasal spray formulations
The FDA approved the first nalmefene hydrochloride auto-injector (Zurnai) for use as an emergency treatment for opioid overdose in adults and children 12 years of age and older, the agency announcedopens in a new tab or window Wednesday.
Nalmefene is an opioid receptor antagonist used to treat acute opioid overdose, initially approved in 2022 as an injectionopens in a new tab or window for use by healthcare professionals and, since May 2023, as a nasal spray formulation (Opvee)opens in a new tab or window. If administered quickly, the treatment can reverse the effects of opioid overdose, such as respiratory depression, sedation, and hypotension.
Tags: Harm Reduction New Drug New Drug Trend Opioid Epidemic Overdose
